An expert discusses how the PEACE III trial demonstrated that combining radium-223 with enzalutamide significantly improved radiographic progression-free survival and overall survival compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC) who had bone metastases and limited prior treatment exposure.
Panelist discusses how patient preference significantly impacts treatment selection and describes the process of involving patients in treatment decisions while considering disease characteristics, cytogenetics, and the fact that higher-risk patients may fare better with specific regimens.
Panelists discuss how clinical trial data support the consistent efficacy of oral selective estrogen receptor degraders (SERDs) across diverse metastatic breast cancer subgroups—including patients with visceral disease, HER2-low tumors, or co-mutations such as PIK3CA—reinforcing the drug’s versatility and value as a treatment option beyond narrowly defined molecular profiles.
Panelists discuss the evolving management of estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer, highlighting the clinical impact of oral selective estrogen receptor degraders (SERDs)—particularly in patients with ESR1 mutations—while emphasizing the importance of biomarker-guided therapy selection and ongoing reassessment to optimize outcomes in the context of prior endocrine and CDK4/6 inhibitor exposure.
An expert discusses how the PEACE III trial demonstrated that combining radium-223 with enzalutamide significantly improved radiographic progression-free survival and overall survival compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC) who had bone metastases and limited prior treatment exposure.
An expert explains that metastatic castration-resistant prostate cancer (mCRPC) treatment is guided by prior therapies, disease features, and genetic profiles—favoring androgen receptor pathway inhibitors (ARPIs) for those without progression, PARP inhibitor combinations for patients with BRCA-mutated disease, and tailored options such as radium-223 for bone metastases or chemotherapy for aggressive, genetically altered tumors—with evolving strategies including radioligand therapies aimed at improving survival while preserving quality of life.
Panelist discusses how frontline CLL treatment has evolved from choosing between continuous oral therapy vs fixed-duration combination therapy to now including new all-oral fixed-duration regimens, explaining the advantages and disadvantages of each approach based on patient preferences.
Christina Poh, MD, discusses the promising data supporting the chemotherapy-free combination of tafasitamab plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma.
Theresa Medina, MD, discusses the C-144-01 study of lifileucel in patients with advanced melanoma.
Arturo Loaiza-Bonilla, MD, MSEd, discusses the potential of disitamab vedotin, toripalimab, and chemotherapy/trastuzumab in first-line treatment.
Biren Saraiya, MD, discusses how he sees findings from the phase 3 AMPLITUDE trial being incorporated into clinical practice for the treatment of metastatic castration-sensitive prostate cancer.
Biren Saraiya, MD, provides background on the phase 3 AMPLITUDE study evaluating niraparib plus abiraterone acetate in metastatic castration-sensitive prostate cancer.
Panelists discuss how interferon therapy (particularly ropeginterferon) can provide better hematologic control over time and potentially modify disease progression in polycythemia vera patients.
Panelists discuss how to approach a 67-year-old man with advanced polycythemia vera who is resistant to hydroxyurea, requiring frequent phlebotomies despite maximum tolerated dosing, and experiencing new symptoms like night sweats and fatigue.
GLP-1 receptor agonists show promise in reducing cancer risk and enhancing early detection, highlighting the need for further research in oncology.
Panelists discuss how diagnosis and staging of anal cancer involves digital rectal examination, high-resolution anoscopy with biopsy, p16 testing, and pelvic MRI for accurate staging, while considering patient factors like HIV status, treatment adherence capability, and comorbidities when planning curative intent therapy.
Panelists discuss how anal cancer epidemiology shows increasing incidence in both sexes with HPV infection as the primary risk factor, affecting predominantly women with a median age of 60, while emphasizing the need to dispel misconceptions linking HPV-related anal cancer to sexual practices.
Surbhi Sidana, MD, discusses updates from the CARTITUDE-4 study assessing the CAR T therapy cilta-cel in patients with multiple myeloma.
Arturo Loaiza-Bonilla, MD, MSEd, discusses findings from the MATTERHORN trial in patients with resectable gastric or gastroesophageal junction adenocarcinoma.
A panelist discusses how patients with advanced cGVHD often cycle through multiple approved agents over time due to plateauing responses, and describes upcoming clinical trials testing upfront use of these novel agents with corticosteroids in newly diagnosed patients to potentially improve outcomes.
Dax Kurbegov, MD, discusses findings from the CORE-HH study that build on growing evidence to support the clinical feasibility of blood-based early detection tools.
The SEQUOIA arm D study demonstrates promising outcomes for treatment-naive patients with CLL, including high-risk patients.
Dale Shepard, MD, PhD, discusses the key themes emerging from the 2025 ASCO Annual Meeting, highlighting a prevailing sense of optimism driven by ongoing research.
Erika Hamilton, MD, shares key insights from the 2025 ASCO Annual Meeting that are set to impact breast cancer treatment.
Pedro C. Barata, MD, MSc, discusses a typical process for an oncologist to patients who are newly diagnosed with metastatic hormone-sensitive prostate cancer.
Ravi Muvner, MD, discusses changing paradigms in prostate cancer treatment.
Jeremy S. Abramson, MD, discusses pivotal advancements in DLBCL from the 2025 American Society of Clinical Oncology Annual Meeting.
An expert emphasizes that treatment decisions for metastatic castration-resistant prostate cancer (mCRPC) are highly personalized, balancing clinical efficacy with patient lifestyle, quality of life, and preferences—prioritizing overall survival alongside minimizing adverse effects and hospital visits—while endorsing flexible treatment durations, including breaks and dose adjustments, to maintain both effectiveness and patient well-being through shared decision-making.